ASCO Offers Glimpse Of LAG-3 Inhibitors’ Potential Opportunities – And Limitations

PD-1-Naïve Patients More Likely To Derive Benefit

 
• By Alaric DeArment

Clinical data released on drugs targeting LAG-3 from BMS, Regeneron, Merck & Co. and Immutep in a variety of cancers.

3d illustration of T cells attacking a cancer cell
Several studies of LAG-3-targeting drugs combined with PD-1 and PD-L1 inhibitors are being presented at ASCO • Source: Shutterstock

More from ASCO

More from Conferences